Overview

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shebli Atrash
Collaborators:
Amgen
GlaxoSmithKline
Treatments:
Dexamethasone
Lenalidomide